Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Completed Phase 1 / 2 Trials for IRX-2 (DB05643)

IndicationStatusPhase
DBCOND0113388 (Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03918499IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction CancerTreatment